Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MOF Asks MHLW for Add’l 10% Price Cut for Long-listed Drugs
December 12, 2011
-
REGULATORY 11 APIs/26 Products to Return Premium for New Drug Development
December 9, 2011
-
REGULATORY Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs
December 8, 2011
-
BUSINESS Towa Pharmaceutical to Expand Dealings with Regional Foundation Hospitals
December 7, 2011
-
BUSINESS Growth for All Products Is Indispensable: President Alvarez of MSD
December 7, 2011
-
BUSINESS Sandoz Aiming for Top-10 Position in Japan within 3-5 Years
December 7, 2011
-
BUSINESS Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales
December 6, 2011
-
REGULATORY MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”
December 6, 2011
-
REGULATORY NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 5, 2011
-
REGULATORY Average Discrepancy Rate Remains at Approximately 8.4%: MHLW Flash Report
December 2, 2011
-
BUSINESS UK AstraZeneca CEO Brennan Says Investment in Japan, a “Very Important Market,” Will Continue
December 1, 2011
-
REGULATORY CSIMC Approves Outline of Plan to Promote Generic Drug Use
December 1, 2011
-
REGULATORY CSIMC Expert Member Yoshimura Says Conditions Must Improve to Promote Generics
November 30, 2011
-
BUSINESS AZ to Bolster Its Top Position in Breast Cancer Area
November 29, 2011
-
REGULATORY Record 101 Generics from 30 Companies Listed for Aricept
November 29, 2011
-
REGULATORY MHLW Says Sept Drug Price Settlement Rate Dips to 78.1%, Falling Below 2009 Level
November 28, 2011
-
REGULATORY CSIMC to Discuss Additional Price Cuts for Long-Listed Drugs
November 28, 2011
-
ORGANIZATION Economic Losses Due to Illness, Injury Total ¥3.3 Tril. Annually in Japan: ACCJ
November 28, 2011
-
REGULATORY DPJ's Subcommittee for PAL Amendment Begins Deliberations Nov. 28, to Compile Opinion by End-Jan
November 25, 2011
-
ORGANIZATION MSF Japan General Director Expresses Concern Over TPP Negotiations, Possible Generics Price Rise
November 25, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…